Bryan Quinn is a partner in Goodwin’s Technology group and a member of the firm’s Capital Markets practice. He represents clients on a broad range of corporate and securities law matters, including capital markets transactions, corporate governance, and mergers and acquisitions.

In capital markets, Bryan advises companies and investment banks on private financings, initial public offerings, SPAC business combinations, and financing transactions by public companies, including equity, debt and convertible debt offerings. He also advises companies on corporate governance matters, including capital structure, public company reporting and SEC compliance. His merger and acquisition experience includes both buy-side and sell-side representations of public and private companies.

Areas of Practice
业务范围
Domaines D’Expertise
TÄTIGKEITSFELDER

Experience

工作经历

EXPÉRIENCE

ERFAHRUNG

Initial Public Offerings

  • A leading provider of a cloud-native platform for software development and IT operations in its $603 million initial public offering of common stock*
  • The CEO and co-founder of a leading search engine in connection with its $1.4 billion initial public offering and dual-class common stock recapitalization*
  • Various underwriters in the $656 million initial public offering of a leading ultra low-cost airline*
  • Various underwriters in the $219 million initial public offering of a leading TV streaming platform*
  • Various underwriters in the $112 million initial public offering of a leading cybersecurity solutions provider*
  • Various underwriters in the $410 million initial public offering of a leading cloud hosting and domain name marketplace*
  • Various underwriters in the $56 million initial public offering of a leading provider of enterprise, cloud-based incentive compensation solutions*
  • Various underwriters in the $345 million initial public offering of a SPAC focused on the cybersecurity industry sector*
  • Various underwriters in the $230 million initial public offering of a clinical stage immuno-oncology company developing tumor-targeted therapies*
  • Various underwriters in the $113 million initial public offering of a clinical stage immune-oncology company developing novel checkpoint therapies to activate macrophages*
  • Various underwriters in the $48 million initial public offering of a specialty pharmaceutical company focused on chronic disorders of the central nervous system*
  • Various underwriters in the $85 million initial public offering of a clinical biologics platform company focused on the global biosimilar market*

SPAC Business Combinations

  • A leading provider of products, services and software that leverage ionizing radiation in medical and industrial applications in its business combination with a special purpose acquisition company (SPAC)*
  • A leading provider of casual games in its business combination with a SPAC*

Other Equity Offerings

  • Various underwriters in connection with a $282 million follow-on offering of common stock of a leading EV charging network provider*
  • The sales agent in connection with a $500 million at-the-market offering*
  • Various underwriters in connection with a $528 million follow-on offering of a retailer of consumables and fresh products*
  • Various underwriters in connection with a $138 million follow-on offering of common stock of a clinical-stage biotechnology company developing next-generation human enzyme therapeutics*
  • Various underwriters in connection with a $347 million follow-on offering of common stock of a biopharmaceutical company focused on the development and commercialization of new medications targeted at inflammatory disorders, autoimmune diseases and cancer*
  • Various underwriters in connection with a $575 million follow-on offering of common stock of a biotechnology company focused on the development and commercialization of targeted therapies for the treatment of cancer*
  • Various underwriters in connection with a $115 million follow-on offering of common stock of a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed*

Convertible Debt Offerings

  • The lead investor in connection with its investment in $300 million of convertible senior notes offered by a leading EV charging network provider*
  • A leading provider of specialty memory, storage and hybrid solutions in connection with its $250 million convertible senior notes offering*
  • Various underwriters in connection with a $1.2 billion offering of convertible senior notes by a leading provider of business intelligence software*
  • Various underwriters in connection with a $600 million offering of convertible senior notes by leading global manufacturer and supplier of discrete semiconductor*
  • A leading solar technology and energy services provider in connection with its $400 million offering of convertible senior notes*

Debt Offerings

  • Multiple high-yield and investment grade debt offerings by a leading financial services company providing brokerage services and related products*
  • A leading datacenter provider in connection with its $1.3 billion inaugural green bonds offering*
  • Various underwriters in connection with a $20 billion investment-grade senior notes offering by a leading provider of enterprise information technology*
  • Various underwriters in connection with a $4 billion investment-grade senior notes offering by a leading digital payments company*
  • Various underwriters in connection with a $575 million high-yield senior notes offering by a leading provider of search technology*
  • Various underwriters in connection with a $550 million investment-grade senior notes offering by a holding company for a group of insurance companies*

Corporate Governance and Public Company Advice

  • Mr. Quinn regularly provides general corporate advice on corporate governance and SEC public reporting matters for various companies

Mergers & Acquisitions

  • A leading provider of a cloud-native platform for software development and IT operations in its $2.7 billion sale to a leading provider of software virtualization technologies*
  • The special committee of a leading semiconductor company in its $37 billion sale to a global supplier analog semiconductor devices*
  • A leading provider of DNA microarray products in its $1.2 billion sale to a leading provider of products for scientists*
  • The special committee of a leading industrial company in its $483 million go-private sale to a consortium of private equity funds*
  • Private company financings and capital restructurings for multiple companies*

*Denotes experience prior to joining Goodwin.

Professional Experience
Prior to joining Goodwin, Mr. Quinn was counsel in the Northern California office of Davis Polk. Before starting his legal career at Davis Polk, he worked for public and private software companies in various business and technical roles.

Recognition

Mr. Quinn has been named a California Rising Star by Super Lawyers.

In The News

相关新闻

ACTUALITÉS

MELDUNGEN

Credentials

专业资格

RÉFÉRENCES

WERDEGANG

Education

J.D.
Georgetown University Law Center
(Order of the Coif, magna cum laude, Articles Editor Georgetown Law Journal)
B.A., Computing Information Systems
Northwestern University

Admissions

Bar

California
U.S. Patent and Trademark Office (USPTO)
Get In Touch
联系我们
NOUS CONTACTER
Kontakt
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Search Other Lawyers
搜寻其他律师
Recherche par Pratique
ANWALTSSUCHE